SAN DIEGO--(BUSINESS WIRE)--Aethlon Medical, Inc. (OTCBB:AEMD) disclosed today that it will pursue the commercialization of its 1st generation Hemopurifier® in India during the course of the next year. The strategy to initiate commercialization in India corresponds with Aethlon’s international objectives and will parallel the company’s effort to advance the Hemopurifier® as a broad-spectrum treatment countermeasure against bioterror and emerging pandemic threats in the United States. “We are going to implement strategies that offer the greatest likelihood of transitioning our science from the labs and into the marketplace,” stated Aethlon Chairman & CEO, James A. Joyce. “Our plans in India will reinforce our goal to establish the industry for medical devices to treat infectious disease.” The Hemopurifier® is a first-in-class medical device designed to mimic the natural immune response of clearing infectious viruses and related toxins from circulation. The technology is positioned to fill the void in treating drug and vaccine resistant viruses.
